Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - insulin, human, recombinant dna origin 100 [iu] (as 70% isophane insulin and 30% regular insulin) - suspension for injection - 100 iu/ml - active: insulin, human, recombinant dna origin 100 [iu] (as 70% isophane insulin and 30% regular insulin) excipient: dibasic sodium phosphate heptahydrate glycerol hydrochloric acid as 10% solution for ph adjustment metacresol phenol protamine sulfate sodium hydroxide as 10% solution for ph adjustment water for injection zinc oxide - humulin is indicated for the treatment of insulin-requiring diabetes mellitus

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - insulin, human, recombinant dna origin 100 [iu] - suspension for injection - 100 iu/ml - active: insulin, human, recombinant dna origin 100 [iu] excipient: dibasic sodium phosphate heptahydrate glycerol hydrochloric acid as 10% solution for ph adjustment metacresol phenol protamine sulfate sodium hydroxide as 10% solution for ph adjustment water for injection zinc oxide - humulin is indicated for the treatment of insulin-requiring diabetes mellitus

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - insulin, human, recombinant dna origin 100 [iu] - solution for injection - 100 iu/ml - active: insulin, human, recombinant dna origin 100 [iu] excipient: glycerol hydrochloric acid as 10% solution for ph adjustment metacresol sodium hydroxide as 10% solution for ph adjustment water for injection - humulin is indicated for the treatment of insulin-requiring diabetes mellitus.

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - prasugrel hydrochloride 10.98mg - film coated tablet - 10 mg - active: prasugrel hydrochloride 10.98mg excipient: croscarmellose sodium glycerol hypromellose iron oxide red iron oxide yellow lactose magnesium stearate mannitol microcrystalline cellulose purified talc titanium dioxide - effient, co-administered with aspirin, is indicated for the prevention of atherothrombotic events (myocardial infarction, stroke and cardiovascular death) in patients with acute coronary syndromes (moderate to high risk unstable angina (ua), non st-segment elevation myocardial infarction (nstemi) or st-segment elevation myocardial infarction (stemi)) who are to undergo percutaneous coronary intervention (pci).

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - prasugrel hydrochloride 5.49mg - film coated tablet - 5 mg - active: prasugrel hydrochloride 5.49mg excipient: croscarmellose sodium glycerol hypromellose iron oxide yellow lactose magnesium stearate mannitol microcrystalline cellulose purified talc titanium dioxide - effient, co-administered with aspirin, is indicated for the prevention of atherothrombotic events (myocardial infarction, stroke and cardiovascular death) in patients with acute coronary syndromes (moderate to high risk unstable angina (ua), non st-segment elevation myocardial infarction (nstemi) or st-segment elevation myocardial infarction (stemi)) who are to undergo percutaneous coronary intervention (pci).

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - fluoxetine hydrochloride 22.36mg equivalent to fluoxetine 20 mg - capsule - 20 mg - active: fluoxetine hydrochloride 22.36mg equivalent to fluoxetine 20 mg excipient: dimeticone gelatin ink iron oxide yellow patent blue v starch titanium dioxide - · depression and it's associated anxiety · bulimia nervosa · obsessive-compulsive disorder and premenstrual dysphoric disorder - a severe form of pms. diagnosis of pmdd: the essential features of pmdd are clear and established cyclicity of symptoms (occurring during the last week of the luteal phase in most menstrual cycles) such as depressed mood, anxiety, affective lability, and physical symptoms such as breast tenderness or swelling, headaches, joint or muscle pain, bloating, and weight gain. pmdd is a severe clinical entity and is distinguished from the broader premenstrual syndrome by the intensity of its symptoms (particularly mood symptoms) and the extent to which it interferes with social and/or occupational function

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - teriparatide 250 µg/ml (rhpth(1-34));   - solution for injection - 250 mcg/ml - active: teriparatide 250 µg/ml (rhpth(1-34))   excipient: glacial acetic acid hydrochloric acid mannitol metacresol sodium acetate sodium hydroxide water for injection - forteo, in combination with calcium and vitamin d, is indicated for the treatment of osteoporosis in postmenopausal women and in men at high risk of fracture.

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - abemaciclib 100mg - film coated tablet - 100 mg - active: abemaciclib 100mg excipient: colloidal silicon dioxide croscarmellose sodium lactose monohydrate macrogol 3350 microcrystalline cellulose polyvinyl alcohol purified talc sodium stearyl fumarate titanium dioxide - early breast cancer verzenio in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients 18 years of age or older with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node-positive early breast cancer at high risk of recurrence. in pre - or peri-menopausal women, endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancer verzenio is indicated for the treatment of adult patients 18 years of age or older with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy or following prior endocrine therapy. in pre -or peri-menopausal women, endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist.

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - abemaciclib 150mg - film coated tablet - 150 mg - active: abemaciclib 150mg excipient: colloidal silicon dioxide croscarmellose sodium iron oxide yellow lactose monohydrate macrogol 3350 microcrystalline cellulose polyvinyl alcohol purified talc sodium stearyl fumarate titanium dioxide - early breast cancer verzenio in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients 18 years of age or older with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node-positive early breast cancer at high risk of recurrence. in pre - or peri-menopausal women, endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancer verzenio is indicated for the treatment of adult patients 18 years of age or older with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy or following prior endocrine therapy. in pre -or peri-menopausal women, endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist.

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - abemaciclib 50mg - film coated tablet - 50 mg - active: abemaciclib 50mg excipient: colloidal silicon dioxide croscarmellose sodium iron oxide red iron oxide yellow lactose monohydrate macrogol 3350 microcrystalline cellulose polyvinyl alcohol purified talc sodium stearyl fumarate titanium dioxide - early breast cancer verzenio in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients 18 years of age or older with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node-positive early breast cancer at high risk of recurrence. in pre - or peri-menopausal women, endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancer verzenio is indicated for the treatment of adult patients 18 years of age or older with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy or following prior endocrine therapy. in pre -or peri-menopausal women, endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist.